Drug elution has come
to the periphery.
Zilver PTX, the world’s first and only drug-eluting stent for the superficial femoral artery (SFA), is now approved in the U.S. Its proven drug effect inhibits restenosis and cuts reintervention rates in half.*
*Ansel G. Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Presented at: the Society for Cardiovascular Angiography
and Interventions (SCAI) 2011; May 4-7, 2011;
Baltimore, Maryland.
Instructions for Use:
Refer to the Instructions for Use (IFU) for full prescribing information, including indications, contraindications, warnings and precautions.
